NasdaqGS:ABCLLife Sciences
Assessing AbCellera Biologics (NasdaqGS:ABCL) Valuation After New Facility Launch and Pipeline Progress
AbCellera Biologics (NasdaqGS:ABCL) recently reported year-over-year revenue growth along with important operational milestones, including activating a clinical manufacturing facility and moving lead drug candidates ABCL635 and ABCL575 into Phase 1 trials. These developments come even as the company reported a wider net loss, largely attributed to higher research and development spending.
See our latest analysis for AbCellera Biologics.
Following these recent clinical and operational...